BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Critical Reviews in Oncology/Hematology 2009;69:259-70. [DOI: 10.1016/j.critrevonc.2008.09.008] [Cited by in Crossref: 99] [Cited by in F6Publishing: 81] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Sritananuwat P, Sueangoen N, Thummarati P, Islam K, Suthiphongchai T. Blocking ERK1/2 signaling impairs TGF-β1 tumor promoting function but enhances its tumor suppressing role in intrahepatic cholangiocarcinoma cells. Cancer Cell Int 2017;17:85. [PMID: 28959141 DOI: 10.1186/s12935-017-0454-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
2 Byrling J, Sasor A, Nilsson J, Said Hilmersson K, Andersson R, Andersson B. Expression of fibroblast activation protein and the clinicopathological relevance in distal cholangiocarcinoma. Scand J Gastroenterol 2020;55:82-9. [PMID: 31917931 DOI: 10.1080/00365521.2019.1708449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018;1864:1435-43. [PMID: 28757170 DOI: 10.1016/j.bbadis.2017.07.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
4 Kawasaki H, Akazawa Y, Razumilava N. Progress toward improving outcomes in patients with cholangiocarcinoma. Curr Treat Options Gastroenterol 2021;19:153-68. [PMID: 33883870 DOI: 10.1007/s11938-021-00333-2] [Reference Citation Analysis]
5 Cai J, Chen W, Hou X, Liang L, Hao X, Yin X. Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism. Anti-Cancer Drugs 2013;24:1020-9. [DOI: 10.1097/cad.0b013e328364f935] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jiang W, Zeng Z, Tang Z, Fan J, Zhou J, Zeng M, Zhang J, Chen Y, Tan Y. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases. J Cancer Res Clin Oncol 2010;136:1323-31. [DOI: 10.1007/s00432-010-0783-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
7 Roth GS, Bichard P, Fior-Gozlan M, Roth H, Auroux J, Risse O, Letoublon C, Laverrière MH, Bricault I, Leroy V, Decaens T. Performance of bile aspiration plus brushing to diagnose malignant biliary strictures during endoscopic retrograde cholangiopancreatography. Endosc Int Open 2016;4:E997-E1003. [PMID: 27652308 DOI: 10.1055/s-0042-108854] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Plengsuriyakarn T, Karbwang J, Na-Bangchang K. Anticancer activity using positron emission tomography-computed tomography and pharmacokinetics of β-eudesmol in human cholangiocarcinoma xenografted nude mouse model. Clin Exp Pharmacol Physiol 2015;42:293-304. [PMID: 25545782 DOI: 10.1111/1440-1681.12354] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
9 Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35:2083-2091. [PMID: 21698503 DOI: 10.1007/s00268-011-1171-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
10 Qian MB, Chen YD, Liang S, Yang GJ, Zhou XN. The global epidemiology of clonorchiasis and its relation with cholangiocarcinoma. Infect Dis Poverty 2012;1:4. [PMID: 23849183 DOI: 10.1186/2049-9957-1-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 10.7] [Reference Citation Analysis]
11 Maroni L, Pierantonelli I, Banales JM, Benedetti A, Marzioni M. The significance of genetics for cholangiocarcinoma development. Ann Transl Med 2013;1:28. [PMID: 25332972 DOI: 10.3978/j.issn.2305-5839.2012.10.04] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
12 Byrling J, Andersson B, Marko-varga G, Andersson R. Cholangiocarcinoma – current classification and challenges towards personalised medicine. Scandinavian Journal of Gastroenterology 2016;51:641-3. [DOI: 10.3109/00365521.2015.1127409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
13 Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging 2014;14:14. [PMID: 25608662 DOI: 10.1186/1470-7330-14-14] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
14 Liu XF, Jiang H, Zhang CS, Yu SP, Wang ZQ, Su HL. Targeted drug regulation on methylation of p53-BAX mitochondrial apoptosis pathway affects the growth of cholangiocarcinoma cells. J Int Med Res 2012;40:67-75. [PMID: 22429346 DOI: 10.1177/147323001204000107] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
15 Zheng W, Ying J, Zhou Y, Lu Z, Min K, Wang W, Zhang Y, Zhang M, Yang J. The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis. J Cancer 2019;10:257-66. [PMID: 30662546 DOI: 10.7150/jca.27487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Chen Y, Pan Y, Shen KR, Zhu XL, Lu CY, Li QH, Han SG, Fu YB, Xu XF, Yu RS. Contrast-enhanced multiple-phase imaging features of intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma with cirrhosis: A comparative study. Oncol Lett 2017;14:4213-9. [PMID: 28943929 DOI: 10.3892/ol.2017.6656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Grunnet M, Mau-Sørensen M. Serum tumor markers in bile duct cancer--a review.Biomarkers. 2014;19:437-443. [PMID: 24857368 DOI: 10.3109/1354750X.2014.923048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 3.9] [Reference Citation Analysis]
18 Qiu H, Liu C, Huang M, Shen S, Wang W. Prognostic Value of Combined CA19-9 with Aspartate Aminotransferase to Lymphocyte Ratio in Patients with Intrahepatic Cholangiocarcinoma After Hepatectomy. Cancer Manag Res 2021;13:5969-80. [PMID: 34377017 DOI: 10.2147/CMAR.S320380] [Reference Citation Analysis]
19 Krings G, Ramachandran R, Jain D, Wu TT, Yeh MM, Torbenson M, Kakar S. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol. 2013;26:782-791. [PMID: 23348905 DOI: 10.1038/modpathol.2012.243] [Cited by in Crossref: 58] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
20 MacKenzie SA, Goffin JS, Rankin C, Carter T. Rare progression of cholangiocarcinoma: distal femoral metastasis. BMJ Case Rep 2017;2017:bcr2016218616. [PMID: 28348262 DOI: 10.1136/bcr-2016-218616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Yeh CN, Chen MH, Chang YC, Wu RC, Tsao LC, Wang SY, Cheng CT, Chiang KC, Chen TW, Hsiao M, Weng WH. Over-expression of TNNI3K is associated with early-stage carcinogenesis of cholangiocarcinoma. Mol Carcinog 2019;58:270-8. [PMID: 30334579 DOI: 10.1002/mc.22925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Matsuda A, Kuno A, Kawamoto T, Matsuzaki H, Irimura T, Ikehara Y, Zen Y, Nakanuma Y, Yamamoto M, Ohkohchi N. Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology. 2010;52:174-182. [PMID: 20578261 DOI: 10.1002/hep.23654] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
23 Wu HJ, Chu PY. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. Int J Mol Sci 2019;20:E4154. [PMID: 31450710 DOI: 10.3390/ijms20174154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
24 Ge X, Wang Y, Wang Y, Li Q, Yu H, Miao L. NK4 Gene Therapy Inhibits HGF/Met-Induced Growth of Human Cholangiocarcinoma Cells. Dig Dis Sci 2013;58:1636-43. [DOI: 10.1007/s10620-012-2523-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. [PMID: 32576609 DOI: 10.1136/esmoopen-2020-000682] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 22.0] [Reference Citation Analysis]
26 Lee BS, Lee SH, Son JH, Jang DK, Chung KH, Paik WH, Ryu JK, Kim YT. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J Gastroenterol Hepatol 2016;31:493-500. [PMID: 26220764 DOI: 10.1111/jgh.13059] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
27 Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J, Jiang W, Zeng MS, Tan YS. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010;10:492. [PMID: 20840777 DOI: 10.1186/1471-2407-10-492] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
28 Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 2012;106:1583-6. [PMID: 22510747 DOI: 10.1038/bjc.2012.144] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
29 Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D. Cholangiocarcinoma: Update and future perspectives. Digestive and Liver Disease 2010;42:253-60. [DOI: 10.1016/j.dld.2009.12.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 98] [Article Influence: 11.2] [Reference Citation Analysis]
30 Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531-3540. [PMID: 20547994 DOI: 10.1200/jco.2009.27.4787] [Cited by in Crossref: 139] [Cited by in F6Publishing: 80] [Article Influence: 12.6] [Reference Citation Analysis]
31 Yoo JJ, Kim C, Chung CW, Jeong YI, Kang DH. 5-aminolevulinic acid-incorporated poly(vinyl alcohol) nanofiber-coated metal stent for application in photodynamic therapy. Int J Nanomedicine 2012;7:1997-2005. [PMID: 22619537 DOI: 10.2147/IJN.S30298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
32 Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F, Rogler G. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer. 2010;10:302. [PMID: 20565817 DOI: 10.1186/1471-2407-10-302] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
33 Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol. 2020;72:95-103. [PMID: 31536748 DOI: 10.1016/j.jhep.2019.09.007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 31.5] [Reference Citation Analysis]
34 Byrling J, Sasor A, Nilsson J, Said Hilmersson K, Andersson R, Andersson B. Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome. Scand J Gastroenterol 2020;55:725-31. [PMID: 32543919 DOI: 10.1080/00365521.2020.1774923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wang K, Zhang H, Xia Y, Liu J, Shen F. Surgical options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6:79-90. [PMID: 28503555 DOI: 10.21037/hbsn.2017.01.06] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
36 Matsuda A, Kuno A, Matsuzaki H, Kawamoto T, Shikanai T, Nakanuma Y, Yamamoto M, Ohkohchi N, Ikehara Y, Shoda J. Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma. J Proteomics. 2013;85:1-11. [PMID: 23612463 DOI: 10.1016/j.jprot.2013.04.017] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
37 Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24:437-443. [PMID: 22261548 DOI: 10.1097/meg.0b013e3283502241] [Cited by in Crossref: 10] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis]
38 Abbas G, Lindor KD. Cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Cancer 2009;40:19-25. [PMID: 19705300 DOI: 10.1007/s12029-009-9085-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
39 Pan TT, Wang W, Jia WD, Xu GL. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncol Lett 2017;13:2957-64. [PMID: 28529557 DOI: 10.3892/ol.2017.5847] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
40 Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol 2014;5:E88-95. [PMID: 25436138 DOI: 10.3978/j.issn.2078-6891.2014.051] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Feliu J, Sastre J, Maurel J, Isla D. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. Clin Transl Oncol 2011;13:536-44. [PMID: 21821487 DOI: 10.1007/s12094-011-0694-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
42 Shu Y, Wang B, Wang J, Wang JM, Zou SQ. Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma. World J Gastroenterol 2011;17:3407-19. [PMID: 21876633 DOI: 10.3748/wjg.v17.i29.3407] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
43 Xiaofang L, Kun T, Shaoping Y, Zaiqiu W, Hailong S. Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma. World J Surg Oncol. 2012;10:5. [PMID: 22230750 DOI: 10.1186/1477-7819-10-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
44 Kwak TW, Shin HJ, Jeong YI, Han ME, Oh SO, Kim HJ, Kim DH, Kang DH. Anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma. Drug Des Devel Ther 2015;9:2201-14. [PMID: 25931814 DOI: 10.2147/DDDT.S80205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
45 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
46 Kuang D, Wang G. Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China 2010;4:371-7. [DOI: 10.1007/s11684-010-0130-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
47 Dizdar Ö, Kılıçkap S. Global Epidemiology of Gastrointestinal Cancers. In: Yalcin S, Philip PA, editors. Textbook of Gastrointestinal Oncology. Cham: Springer International Publishing; 2019. pp. 1-12. [DOI: 10.1007/978-3-030-18890-0_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
48 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
49 Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist 2017;22:804-10. [PMID: 28487467 DOI: 10.1634/theoncologist.2016-0415] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 10.5] [Reference Citation Analysis]
50 Arnold A, Bahra M, Lenze D, Bradtmöller M, Guse K, Gehlhaar C, Bläker H, Heppner FL, Koch A. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay. Experimental and Molecular Pathology 2015;99:344-53. [DOI: 10.1016/j.yexmp.2015.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
51 Jing G, Yuan K, Turk AN, Jhala NC, Arnoletti JP, Zhang K, McDonald JM, Chen Y. Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis. Lab Invest 2011;91:896-904. [PMID: 21464824 DOI: 10.1038/labinvest.2011.60] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
52 Rial NS, Gilchrist KB, Henderson JT, Bhattacharyya AK, Boyer TD, Nadir A, Cunningham JT. Endoscopic ultrasound with biopsy of omental mass for cholangiocarcinoma diagnosis in cirrhosis. World J Gastrointest Endosc 2011;3:124-8. [PMID: 21860680 DOI: 10.4253/wjge.v3.i6.124] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
53 Jongthawin J, Chusorn P, Techasen A, Loilome W, Boonmars T, Thanan R, Puapairoj A, Khuntikeo N, Tassaneeyakul W, Yongvanit P, Namwat N. PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression. Tumour Biol 2014;35:8051-64. [PMID: 24839005 DOI: 10.1007/s13277-014-2021-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
54 Liu ZH, Ma YL, He YP, Zhang P, Zhou YK, Qin H. Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Mol Biol Rep. 2011;38:1769-1775. [PMID: 20835928 DOI: 10.1007/s11033-010-0291-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
55 Di Giorgio A, Sgarbura O, Rotolo S, Schena CA, Bagalà C, Inzani F, Russo A, Chiantera V, Pacelli F. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma. Ther Adv Med Oncol 2020;12:1758835920940887. [PMID: 32782488 DOI: 10.1177/1758835920940887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
56 Kirstein MM, Vogel A. Epidemiology and Risk Factors of Cholangiocarcinoma. Visc Med. 2016;32:395-400. [PMID: 28229073 DOI: 10.1159/000453013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 12.6] [Reference Citation Analysis]
57 Geramizadeh B, Ghavvas R, Kazemi K, Shamsaeefar A, Nikeghbalian S, Malekhosseini SA. Cholangiocarcinoma Secondary to Primary Sclerosing Cholangitis in Explanted Livers: A Single-Center Study in the South of Iran. Hepat Mon 2015;15:e33626. [PMID: 26977169 DOI: 10.5812/hepatmon.33626] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
58 Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. PLoS One 2015;10:e0120545. [PMID: 25799509 DOI: 10.1371/journal.pone.0120545] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
59 Amornpisutt R, Proungvitaya S, Jearanaikoon P, Limpaiboon T. DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma. Tumour Biol. 2015;36:4973-4978. [PMID: 25652468 DOI: 10.1007/s13277-015-3147-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
60 Cho KM, Park H, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ. Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. Oncotarget 2017;8:79441-52. [PMID: 29108323 DOI: 10.18632/oncotarget.18345] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
61 Tawarungruang C, Khuntikeo N, Chamadol N, Laopaiboon V, Thuanman J, Thinkhamrop K, Kelly M, Thinkhamrop B. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification. BMC Cancer 2021;21:497. [PMID: 33941120 DOI: 10.1186/s12885-021-08247-z] [Reference Citation Analysis]
62 Waisberg DR, Pinheiro RS, Nacif LS, Rocha-Santos V, Martino RB, Arantes RM, Ducatti L, Lai Q, Andraus W, D'Albuquerque LC. Resection for intrahepatic cholangiocellular cancer: new advances. Transl Gastroenterol Hepatol 2018;3:60. [PMID: 30363713 DOI: 10.21037/tgh.2018.08.03] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
63 Yang H, Zhou J, Mi J, Ma K, Fan Y, Ning J, Wang C, Wei X, Zhao H, Li E. HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma. Oncol Rep. 2015;34:1681-1691. [PMID: 26260613 DOI: 10.3892/or.2015.4194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
64 Hu H, Tan C, Liu X, Luo F, Li K. Upregulation of the MCL-1S protein variant following dihydroartemisinin treatment induces apoptosis in cholangiocarcinoma cells. Oncol Lett 2015;10:3545-50. [PMID: 26788167 DOI: 10.3892/ol.2015.3760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
65 Rial NS, Henderson JT, Bhattacharyya AK, Nadir A, Cunningham JT. Use of endoscopic ultrasound for diagnosis of cholangiocarcinoma in auto-immune hepatitis. World J Gastrointest Endosc 2010;2:404-7. [PMID: 21191514 DOI: 10.4253/wjge.v2.i12.404] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
66 Chikhale M, Toi PC, Siddaraju N, Ananthakrishnan R. The strength of cytomorphology and efficacy of immuno-cytochemistry in distinguishing hepatocellular carcinoma from its mimics on fine-needle aspiration cytology. Diagn Cytopathol 2021;49:864-75. [PMID: 33929782 DOI: 10.1002/dc.24759] [Reference Citation Analysis]
67 Beyazit Y, Purnak T, Suvak B, Kurt M, Sayilir A, Turhan T, Tas A, Torun S, Celik T, Ibis M, Haznedaroglu IC. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clinics and Research in Hepatology and Gastroenterology 2011;35:644-9. [DOI: 10.1016/j.clinre.2011.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
68 Yang L, Shan J, Shan L, Saxena A, Bester L, Morris DL. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 2015;6:570-88. [PMID: 26487951 DOI: 10.3978/j.issn.2078-6891.2015.055] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
69 Massani M, Bonariol L, Stecca T. Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. J Clin Med 2021;10:2552. [PMID: 34207700 DOI: 10.3390/jcm10122552] [Reference Citation Analysis]
70 Simile MM, Bagella P, Vidili G, Spanu A, Manetti R, Seddaiu MA, Babudieri S, Madeddu G, Serra PA, Altana M, Paliogiannis P. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina (Kaunas) 2019;55:E42. [PMID: 30743998 DOI: 10.3390/medicina55020042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
71 Yang H, Lu X, Liu Z, Chen L, Xu Y, Wang Y, Wei G, Chen Y. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget. 2015;6:6310-6325. [PMID: 25749036 DOI: 10.18632/oncotarget.3355] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
72 Lee J, Yoon WS, Koom WS, Rim CH. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 2019;195:93-102. [DOI: 10.1007/s00066-018-1367-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
73 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Reference Citation Analysis]
74 Deng L, Wang Y, Yang J, Li J, Chen Z, Bao W, Chen K, Yao X, Zheng C, Zheng J, Yu Z, Jin B, Chen G. Diffuse reduction of spleen density is a novel prognostic marker for intrahepatic cholangiocarcinoma after curative resection. WJGO 2021;13:929-42. [DOI: 10.4251/wjgo.v13.i8.929] [Reference Citation Analysis]
75 Lange S, Lampe J, Bossow S, Zimmermann M, Neubert W, Bitzer M, Lauer UM. A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma. Hum Gene Ther 2013;24:554-64. [PMID: 23550539 DOI: 10.1089/hum.2012.136] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
76 Lee BS, Hwang JH, Lee SH, Jang SE, Ahn DW, Hwang DW, Cho JY, Yoon YS, Han HS, Ahn S. Older adults with biliary tract cancer: treatment and prognosis. J Am Geriatr Soc 2012;60:1862-71. [PMID: 23035728 DOI: 10.1111/j.1532-5415.2012.04163.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
77 Wu Z, Boonmars T, Boonjaraspinyo S, Nagano I, Pinlaor S, Puapairoj A, Yongvanit P, Takahashi Y. Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection. Parasitol Res 2011;109:657-73. [DOI: 10.1007/s00436-011-2298-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
78 Dai J, Wang H, Dong Y, Zhang Y, Wang J. Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway. Cancer Invest 2013;31:111-20. [PMID: 23362950 DOI: 10.3109/07357907.2012.762781] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
79 Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20:3779-3786. [PMID: 23846786 DOI: 10.1245/s10434-013-3127-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
80 Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:221-232. [PMID: 25966423 DOI: 10.1016/j.bpg.2015.02.003] [Cited by in Crossref: 190] [Cited by in F6Publishing: 139] [Article Influence: 31.7] [Reference Citation Analysis]
81 Byrling J, Kristl T, Hu D, Pla I, Sanchez A, Sasor A, Andersson R, Marko-Varga G, Andersson B. Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker. J Transl Med 2020;18:343. [PMID: 32887625 DOI: 10.1186/s12967-020-02498-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]